======= ATP6V0A2 ======= == Gene Information == * **Official Symbol**: ATP6V0A2 * **Official Name**: ATPase H+ transporting V0 subunit a2 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=23545|23545]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q9Y487|Q9Y487]] * **Interactions**: [[https://thebiogrid.org/search.php?search=ATP6V0A2&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20ATP6V0A2|Open PubMed]] * **OMIM**: [[https://omim.org/entry/611716|Open OMIM]] == Function Summary == * **Entrez Summary**: The protein encoded by this gene is a subunit of the vacuolar ATPase (v-ATPase), an heteromultimeric enzyme that is present in intracellular vesicles and in the plasma membrane of specialized cells, and which is essential for the acidification of diverse cellular components. V-ATPase is comprised of a membrane peripheral V(1) domain for ATP hydrolysis, and an integral membrane V(0) domain for proton translocation. The subunit encoded by this gene is a component of the V(0) domain. Mutations in this gene are a cause of both cutis laxa type II and wrinkly skin syndrome. [provided by RefSeq, Jul 2009]. * **UniProt Summary**: Part of the proton channel of V-ATPases. Essential component of the endosomal pH-sensing machinery. May play a role in maintaining the Golgi functions, such as glycosylation maturation, by controlling the Golgi pH. In aerobic conditions, involved in intracellular iron homeostasis, thus triggering the activity of Fe(2+) prolyl hydroxylase (PHD) enzymes, and leading to HIF1A hydroxylation and subsequent proteasomal degradation (PubMed:28296633). {ECO:0000269|PubMed:16415858, ECO:0000269|PubMed:18157129, ECO:0000269|PubMed:28296633}. |V ATPase I| |vacuolar proton-transporting V-type ATPase, V0 domain| |vacuolar proton-transporting V-type ATPase complex| |cellular response to increased oxygen levels| |vacuolar acidification| |proton-transporting ATPase activity, rotational mechanism| |response to increased oxygen levels| |phagosome acidification| |transferrin transport| |phagosome maturation| |intracellular pH reduction| |pH reduction| |cellular iron ion homeostasis| |iron ion transport| |phagocytic vesicle membrane| |ATPase binding| |iron ion homeostasis| |regulation of intracellular pH| |acrosomal vesicle| |insulin receptor signaling pathway| |regulation of cellular pH| |regulation of pH| |cellular transition metal ion homeostasis| |cellular monovalent inorganic cation homeostasis| |transition metal ion transport| |transition metal ion homeostasis| |monovalent inorganic cation homeostasis| |proton transmembrane transport| |cellular response to insulin stimulus| |regulation of macroautophagy| |endosome membrane| |cellular response to oxygen levels| |response to insulin| |cellular response to peptide hormone stimulus| |lysosomal membrane| |cellular response to peptide| |regulation of autophagy| |response to oxygen levels| |response to peptide hormone| |monovalent inorganic cation transport| |response to peptide| |transmembrane receptor protein tyrosine kinase signaling pathway| |cellular metal ion homeostasis| |inorganic cation transmembrane transport| |cellular response to organonitrogen compound| |cellular response to hormone stimulus| |cation transmembrane transport| |metal ion homeostasis| |cellular cation homeostasis| |metal ion transport| |cellular ion homeostasis| |inorganic ion transmembrane transport| |cellular response to nitrogen compound| |perinuclear region of cytoplasm| |cation homeostasis| |enzyme linked receptor protein signaling pathway| |inorganic ion homeostasis| |cellular chemical homeostasis| |ion homeostasis| |cation transport| |regulation of cellular catabolic process| |cellular homeostasis| |response to hormone| |ion transmembrane transport| |regulation of catabolic process| |response to organonitrogen compound| |cellular response to oxygen-containing compound| |response to nitrogen compound| |chemical homeostasis| |response to abiotic stimulus| |cellular response to endogenous stimulus| |transmembrane transport| |ion transport| |response to endogenous stimulus| |protein transport| |peptide transport| |response to oxygen-containing compound| |amide transport| |establishment of protein localization| |homeostatic process| |nitrogen compound transport| |immune response| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp454|Bafilomycin-A1 0.009μM R08 exp454]]|-4.63| |[[:results:exp90|WYE-354 6μM R02 exp90]]|-4.44| |[[:results:exp435|JQ1 0.8μM R08 exp435]]|-3.94| |[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|-3.47| |[[:results:exp17|DABN 20μM R00 exp17]]|-3.4| |[[:results:exp79|Q15 2.7μM R02 exp79]]|-3.31| |[[:results:exp169|BH1 1μM R04 exp169]]|-3.25| |[[:results:exp227|Cryptotanshinone 12μM R05 exp227]]|-3.05| |[[:results:exp466|Cannabidiol 20μM R08 exp466]]|-2.98| |[[:results:exp329|Hydroxyurea 100μM R07 exp329]]|-2.87| |[[:results:exp469|CFI-400945 25μM R08 exp469]]|-2.84| |[[:results:exp216|Erlotinib 10μM R05 exp216]]|-2.81| |[[:results:exp357|Dorsomorphin 5μM R07 exp357]]|-2.77| |[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|-2.67| |[[:results:exp346|CoCl2 18μM R07 exp346]]|-2.66| |[[:results:exp68|Clomiphene 4.4μM R02 exp68]]|-2.65| |[[:results:exp504|MK2206 4μM R08 exp504]]|-2.62| |[[:results:exp524|Staurosporine 0.02μM R08 exp524]]|-2.54| |[[:results:exp24|Nocodazole 0.2μM R00 exp24]]|-2.52| |[[:results:exp539|42°C R08 exp539]]|-2.49| |[[:results:exp320|ABT-702 5μM plus CoCl2 18μM R07 exp320]]|-2.42| |[[:results:exp26|Oligomycin-A 20μM R00 exp26]]|-2.39| |[[:results:exp401|SNS-032 25μM R07 exp401]]|-2.35| |[[:results:exp445|∆-9-Tetrahydrocannabinol 30μM R08 exp445]]|-2.35| |[[:results:exp442|Ibrutinib 10μM R08 exp442]]|-2.32| |[[:results:exp350|Deferoxamine 11μM R07 exp350]]|-2.21| |[[:results:exp515|PU-H71 1μM R08 exp515]]|-2.21| |[[:results:exp492|iCRT14 30μM R08 exp492]]|-2.19| |[[:results:exp436|Dynasore 7μM R08 exp436]]|-2.18| |[[:results:exp22|MLN-4924 2μM R00 exp22]]|-2.18| |[[:results:exp382|Palbociclib 1μM R07 exp382]]|-2.18| |[[:results:exp334|All-trans-Retinoic-Acid 40μM R07 exp334]]|-2.17| |[[:results:exp440|Aphidicolin 0.4μM R08 exp440]]|-2.16| |[[:results:exp151|SGC0946 7μM R03 exp151]]|-2.16| |[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|-2.15| |[[:results:exp4|Actinomycin-D 0.01μM R00 exp4]]|-2.07| |[[:results:exp455|Benzoate 10000μM R08 exp455]]|-2.06| |[[:results:exp416|Tubacin 1.6μM R07 exp416]]|-2.06| |[[:results:exp470|Chloroquine 32μM R08 exp470]]|-2.04| |[[:results:exp164|Q15 1 to 2μM on day4 R04 exp164]]|-2.03| |[[:results:exp487|Hinokiflavone 12μM R08 exp487]]|-1.98| |[[:results:exp128|GSK591 2.6μM R03 exp128]]|-1.96| |[[:results:exp456|Benzoate 20000μM R08 exp456]]|-1.95| |[[:results:exp290|LLY-283 2.6μM R06 exp290]]|-1.94| |[[:results:exp2|5-Fluorouracil 20μM R00 exp2]]|-1.93| |[[:results:exp182|IU1-47 25μM R04 exp182]]|-1.93| |[[:results:exp28|Pimelic-diphenylamide-106 5μM R00 exp28]]|-1.89| |[[:results:exp160|Ribavirin 10 to 15μM on day4 R04 exp160]]|-1.87| |[[:results:exp81|Selumetinib 20μM R02 exp81]]|-1.86| |[[:results:exp444|THZ531 0.225μM R08 exp444]]|-1.85| |[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|-1.8| |[[:results:exp459|Bleomycin 5μM R08 exp459]]|-1.8| |[[:results:exp433|LJH685 50μM R08 exp433]]|-1.75| |[[:results:exp510|Nicotine 3000μM R08 exp510]]|-1.75| |[[:results:exp527|Tanespimycin 14μM R08 exp527]]|-1.75| |[[:results:exp222|Betulinic acid 10 to 15μM on day4 R05 exp222]]|-1.72| |[[:results:exp431|Rotenone 0.07μM R08 exp431]]|1.7| |[[:results:exp301|VER-155008 3.9μM R06 exp301]]|1.96| |[[:results:exp399|Salubrinal 20μM R07 exp399]]|2| |[[:results:exp288|HMS-I2 10μM R06 exp288]]|2.09| ^Gene^Correlation^ |[[:human genes:w:wdr7|WDR7]]|0.639| |[[:human genes:p:prim1|PRIM1]]|0.583| |[[:human genes:z:zfat|ZFAT]]|0.546| |[[:human genes:t:tgfbrap1|TGFBRAP1]]|0.453| |[[:human genes:a:atp6v1d|ATP6V1D]]|0.447| |[[:human genes:g:gpr107|GPR107]]|0.443| |[[:human genes:a:arl1|ARL1]]|0.434| |[[:human genes:a:atp6v1g1|ATP6V1G1]]|0.43| |[[:human genes:p:pi4kb|PI4KB]]|0.413| |[[:human genes:s:slc39a9|SLC39A9]]|0.412| |[[:human genes:v:vps54|VPS54]]|0.403| |[[:human genes:a:atp6v0b|ATP6V0B]]|0.402| Global Fraction of Cell Lines Where Essential: 3/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|2/28| |bone|0/26| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 1315 * **Expression level (log2 read counts)**: 6.82 {{:chemogenomics:nalm6 dist.png?nolink |}}